Four Key Markets Set For Moderated Growth In 2012

BMI View: While 2012 is set to be an unusually difficult year for drugmakers in Central Europe, we maintain our view that the long-term growth potential of this region is favourable, particularly when compared to the stagnant, limited growth expected in Western Europe. New pharmaceutical austerity measures are now set to come into force in four of the key markets in the region, with price cuts, new limits on reimbursement expenditure and new measures to increase generic substitution and control drug consumption core trends throughout.

To read the full article, please choose one of the following options: